Sulková S, Laurincová Z, Lapcík O, Dlhopolcek P, Stodolová E, Komonová D
Cas Lek Cesk. 1989 Jan 2;128(1):16-9.
In a group of 60 patients dialyzed for more than three years laboratory signs of aluminum accumulation were found in 30%. Serum Al values correlated with the increment in the desferal test. Orally administered aluminium hydroxide is a significant source of Al accumulation, as has been demonstrated by the decline of the blood aluminium level after its discontinuation and a negative desferal test in patients to whom it was not prescribed. The passage of Al across the dialyzation membrane depends on the difference between the ultrafiltrable ratio of the blood value and the Al concentration in the dialyzate. Therefore even a concentration of 10 micrograms/l Al in the dilyzate, so far recommended as "safe", can lead to a rise of the Al blood level during haemodialysis and to Al accumulation in tissues. Effective removal of Al from the organism is possible only during haemodialysis after previous administration of Desferal. Unless an adequate substitute of aluminium hydroxide will be available and a completely aluminium free dialyzate, Al accumulation can be prevented by preventive administration of Desferal.
在一组60例接受透析三年以上的患者中，30%出现了铝蓄积的实验室指标。血清铝值与去铁胺试验的增量相关。口服氢氧化铝是铝蓄积的一个重要来源，这已通过停药后血铝水平的下降以及未服用该药患者去铁胺试验呈阴性得到证实。铝通过透析膜的过程取决于血液中可超滤比例与透析液中铝浓度之间的差异。因此，即使透析液中铝浓度为10微克/升（目前被推荐为“安全”浓度），在血液透析过程中也会导致血铝水平升高以及组织中的铝蓄积。只有在预先给予去铁胺后进行血液透析时，才有可能有效清除体内的铝。除非能有氢氧化铝的适当替代品以及完全不含铝的透析液，否则通过预防性给予去铁胺可以预防铝蓄积。
